Ferritin as an important player in neurodegeneration

Parkinsonism and Related Disorders

Volumn 17, Issue 6, 2011, Pages 423-430

  Friedman, Andrzej ^a   Arosio, Paolo ^b   Finazzi, Dario ^b   Koziorowski, Dariusz ^a   Galazka Friedman, Jolanta ^c  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b UNIVERSITY OF BRESCIA   (Italy)

^c WARSAW UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

Ferritin; Iron; Neurodegeneration; Oxidative stress

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATASE TYPE 13A2; CERULOPLASMIN; FATTY ACID 2 HYDROXYLASE; FERRITIN; FERRITIN H; FERRITIN L; IRON; OXYGENASE; PANTOTHENATE KINASE 2; PHOSPHOLIPASE A2; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ATP13A2 GENE; BRAIN TISSUE; CP GENE; DEGENERATIVE DISEASE; ELECTRON MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; FA2H GENE; FENTON REACTION; FTH GENE; FTL GENE; GENE MUTATION; HUMAN; IRON STORAGE; MOSSBAUER SPECTROSCOPY; NERVE CELL NECROSIS; NERVE DEGENERATION; NEURODEGENERATION WITH BRAIN IRON ACCUMULATION; NEUROFERRITINOPATHY; OXIDATIVE STRESS; PARKINSON DISEASE; PKAN GENE; PLA2G6 GENE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; REVIEW;

ANIMALS; BRAIN CHEMISTRY; FERRITINS; HUMANS; NEURODEGENERATIVE DISEASES; OXIDATIVE STRESS;

EID: 79959523068     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2011.03.016     Document Type: Review

References (85)

1. Halliwell B. Mechanisms involved in the generation of free radicals. Pathol Biol 1996, 44:6-13.
2. Barnham K.J., Masters C.L., Bush A.I. Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov 2004, 3:205-214.
3. Spiteller G. Peroxyl radicals: inductors of neurodegenerative and other inflammatory diseases. Their origin and how they transform cholesterol, phospholipids, plasmalogens, polyunsaturated fatty acids, sugars, and proteins into deleterious products. Free Radic Biol Med 2006, 41:362-387.
4. Harrison P.M., Arosio P. The ferritins: molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta 1996, 1275:161-203.
5. Arosio P., Ingrassia R., Cavadini P. Ferritins: a family of molecules for iron storage, antioxidation and more. Biochim Biophys Acta 2009, 1790:589-599.
6. Bou-Abdallah F. The iron redox and hydrolysis chemistry of the ferritins. Biochim Biophys Acta 1800, 2010:719-731.
7. Levi S., Corsi B., Rovidan E., Cozzi A., Santambrogio P., Albertinill A., et al. Construction of a ferroxidase center in human ferritin L-chain. J Biol Chem 1994, 269:30334-30339.
8. Zhao G., Bou-Abdallahl F., Yang X., Arosio P., Chasteen D. Iron(II) and hydrogen peroxide detoxification by human H-chain ferritin. An EPR spin-trapping study. Biochemistry 2006, 45:3429-3436.
9. Santambrogio P., Levi S., Cozzi A., Rovida E., Albertini A., Arosio A. Production and characterization of recombinant heteropolymers of human ferritin H and L chains. J Biol Chem 1993, 268:12744-12748.
10. Shi H., Bencze K.Z., Stemmler T.L., Philpott C.C. A cytosolic iron chaperone that delivers iron to ferritin. Science 2008, 320:1207-1210.
11. Chasteen N.D. Ferritin. Uptake, storage, and release of iron. Met Ions Biol Syst 1998, 35:479-514.
12. Cassanelli S., Moulis J. Sulfide is an efficient iron releasing agent for mammalian ferritins. Biochim Biophys Acta 2001, 1547:174-182.
13. Theil E.C., Matzapetakis M., Liu X. Ferritins: iron/oxygen biominerals in protein nanocages. J Biol Inorg Chem 2006, 11:803-810.
14. Hasan M.R., Tosha T., Theil E.C. Ferritin contains less iron (59Fe) in cells when the protein pores are unfolded by mutation. J Biol Chem 2008, 283:31394-31400.
15. Jin W., Takagi H., Pancorbo B., Theil E.C. "Opening" the ferritin pore for iron release by mutation of conserved amino acids at interhelix and loop sites. Biochemistry 2001, 40:7525-7532.
16. Cozzi A., Rovelli E., Frizzale G., Campanella A., Amendola M., Arosio P., et al. Oxidative stress and cell death in cells expressing L-ferritin variants causing neuroferritinopathy. Neurobiol Dis 2009, 37:77-85.
17. Cozzi A., Santambrogio P., Corsi B., Campanella A., Arosio P., Levi S. Characterization of the l-ferritin variant 460InsA responsible of a hereditary ferritinopathy disorder. Neurobiol Dis 2006, 23:644-652.
18. Luscieti S., Santambrogio P., Langlois d'Estaintot B., Granier T., Cozzi A., Poli M., et al. Mutant ferritin L-chains that cause neurodegeneration act in a dominant-negative manner to reduce ferritin iron incorporation. J Biol Chem 2010, 285:11948-11957.
19. Harrison P.M., Hoy T.G., Macara I.G., Hoare R.J. Ferritin iron uptake and release. Structure-function relationships. Biochem J 1974, 143:445-451.
20. Larson J.A., Howie H.L., So M. Neisseria meningitidis accelerates ferritin degradation in host epithelial cells to yield an essential iron source. Mol Microbiol 2004, 53:807-820.
21. Kidane T.Z., Sauble E., Linder M.C. Release of iron from ferritin requires lysosomal activity. Am J Physiol, Cell Physiol 2006, 291:C445-C455.
22. Mehlhase J., Sandig G., Pantopoulos K., Grune T. Oxidation-induced ferritin turnover in microglial cells: role of proteasome. Free Radic Biol Med 2005, 38:276-285.
23. De Domenico I., Vaughn M.B., Li L., Bagley D., Musci G., Ward D.M., et al. Ferroportin-mediated mobilization of ferritin iron precedes ferritin degradation by the proteasome. EMBO J 2006, 25:5396-5404.
24. De Domenico I., Vaughn M.B., Li L., Bagley D., Musci G., Ward D.M., et al. Specific iron chelators determine the route of ferritin degradation. Blood 2009, 25:5396-5404.
25. Levi S., Corsi B., Bosisio M., Invernizzi R., Volz A., Sanford D., et al. A human mitochondrial ferritin encoded by an intronless gene. J Biol Chem 2001, 276:24437-24440.
26. Missirlis F., Holmberg S., Georgieva T., Dunkov B.C., Rouault T.A., Law J.H. Characterization of mitochondrial ferritin in Drosophila. Proc Natl Acad Sci USA 2006, 103:5893-5898.
27. Zancani M., Peresson C., Biroccio A., Federici G., Urbani A., Murgia I., et al. Evidence for the presence of ferritin in plant mitochondria. Eur J Biochem 2004, 271:3657-3664.
28. Corsi B., Cozzi A., Arosio P., Drysdale J., Santambrogio P., Campanella A., et al. Human mitochondrial ferritin expressed in HeLa cells incorporates iron and affects cellular iron metabolism. J Biol Chem 2002, 277:22430-22437.
29. Drysdale J., Arosio P., Invernizzi R., Cazzola M., Volz A., Corsi B., et al. Mitochondrial ferritin: a new player in iron metabolism. Blood Cells Mol Dis 2002, 29:376-383.
30. Levi S., Arosio P. Mitochondrial ferritin. Int J Biochem Cell Biol 2004, 36:1887-1889.
31. Cazzola M., Invernizzi R., Bergamaschi G., Levi S., Corsi B., Travaglino E., et al. Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia. Blood 2003, 101:1996-2000.
32. Santambrogio P., Biasiotto G., Sanvito F., Olivieri S., Arosio P., Levi S. Mitochondrial ferritin expression in adult mouse tissues. J Histochem Cytochem 2007, 55:1129-1137.
33. Snyder A.M., Neely E.B., Levi S., Arosio P., Connor J.R. Regional and cellular distribution of mitochondrial ferritin in the mouse brain. J Neurosci Res 2010, 88:3133-3143.
34. Langlois d'Estaintot B., Santambrogio P., Granier T., Gallois B., Chevalier J.M., Précigoux G., et al. Crystal structure and biochemical properties of the human mitochondrial ferritin and its mutant Ser144Ala. J Mol Biol 2004, 340:277-293.
35. Bou-Abdallah F., Santambrogio P., Levi S., Arosio P., Chasteen N.D. Unique iron binding and oxidation properties of human mitochondrial ferritin: a comparative analysis with human H-chain ferritin. J Mol Biol 2005, 347:543-554.
36. Nie G., Sheftel A.D., Kim S.F., Ponka P. Overexpression of mitochondrial ferritin causes cytosolic iron depletion and changes cellular iron homeostasis. Blood 2005, 105:2161-2167.
37. Campanella A., Isaya G., O'Neill H.A., Santambrogio P., Cozzi A., Arosio P., et al. The expression of human mitochondrial ferritin rescues respiratory function in frataxin-deficient yeast. Hum Mol Genet 2004, 13:2279-2288.
38. Campanella A., Rovelli E., Santambrogio P., Cozzi A., Taroni F., Levi S. Mitochondrial ferritin limits oxidative damage regulating mitochondrial iron availability: hypothesis for a protective role in Friedreich ataxia. Hum Mol Genet 2009, 18:1-11.
39. Zanella I., Derosas M., Corrado M., Cocco E., Cavadini P., Biasiotto G., et al. The effects of frataxin silencing in HeLa cells are rescued by the expression of human mitochondrial ferritin. Biochim Biophys Acta 2008, 1782:90-98.
40. Cavadini P., Biasiotto G., Poli M., Levi S., Verardi R., Zanella I., et al. RNA silencing of the mitochondrial ABCB7 transporter in HeLa cells causes an iron-deficient phenotype with mitochondrial iron overload. Blood 2007, 109:3552-3559.
41. Shi Z.H., Nie G., Duan X.L., Rouault T., Wu W.S., Ning B., et al. Neuroprotective mechanism of mitochondrial ferritin on 6-Hydroxydopamine-induced Dopaminergic cell damage: implication for Neuroprotection in Parkinson's disease. Antioxid Redox Signal 2010, 13:783-796.
42. LaVaute T., Smith S., Cooperman S., Iwai K., Land W., Meyron-Holtz E., et al. Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nat Genet 2001, 27:209-214.
43. Snyder A.M., Wang X., Patton S.M., Arosio P., Levi S., Earley C.J., et al. Mitochondrial ferritin in the substantia nigra in restless legs syndrome. J Neuropathol Exp Neurol 2009, 68:1193-1199.
44. Bartnikas T.B., Campagna D.R., Antiochos B., Mulhern H., Pondarré C., Fleming M.D. Characterization of mitochondrial ferritin-deficient mice. Am J Hematol 2010 Sep, 15. [Epub ahead of print].
45. Galazka-Friedman J., Bauminger E.R., Friedman A., Barcikowska M., Hechel D., Nowik I. Iron in parkinsonian and control substantia nigra - a Mössbauer spectroscopy study. Mov Disord 1996, 11:8-16.
46. Koziorowski D., Friedman A., Arosio Santambrogio P., Dziewulska D. ELISA reveals a difference in the structure of substantia nigra ferritin in Parkinson's disease and Incidental Lewy Body compared to control. Parkinsonism Relat Disord 2007, 13:214-218.
47. Gałazka-Friedman J., Bauminger E.R., Szlachta K., Koziorowski D., Tomasiuk R., Jaklewicz A., et al. Iron in Alzheimer's and control hippocampi - Mössbauer, atomic absorption and ELISA studies. Acta Phys Pol 2011, 119:81-83.
48. Galazka-Friedman J., Bauminger E.R., Tymosz T., Friedman A. Mssbauer spectroscopy, electron microscopy and electron diffraction studies of ferritin-like iron in human heart, liver and brain. Hyperfine Interactions (C) 1998, 3:49-52.
49. Sofic E., Riederer P., Heinsen H., Beckmann H., Reynolds G.P., Hebenstreit G., et al. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm 1988, 74:199-205.
50. Bancroft G.M. Mssbauer spectroscopy - an introduction for inorganic chemists and geochemists 1973, McGraw Hill Book Company, London.
51. Gałazka-Friedman J., Friedman A. Controversies about iron in parkinsonian and control substantia nigra. Acta Neurobiol Exp 1997, 57:210-225.
52. Kruer M.C., Paisan-Ruiz C., Boddaert N., Yoon M.Y., Hama H., Gregory A., et al. Defective FA2H leads to a novel form of neurodegeneration with brain iron accumulation (NBIA). Ann Neurol 2010, 68:611-618.
53. Schneider S.A., Paisan-Ruiz C., Quinn N.P., Lees A.J., Houlden H., Hardy J., et al. ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation. Mov Disord 2010, 25:979-984.
54. Gregory A., Hayflick S.J. Pantothenate kinase-associated neurodegeneration 1993, GeneReviews [Internet], University of Washington, Seattle, Seattle (WA). http://www.ncbi.nlm.nih.gov/books/NBK1490/, R.A. Pagon, T.C. Bird, C.R. Dolan, K. Stephens (Eds.).
55. Perry T.L., Norman M.G., Yong V.W., Whiting S., Crichton J.U., Hansen S., et al. Hallervorden-Spatz disease: cysteine accumulation and cysteine dioxygenase deficiency in the globus pallidus. Ann Neurol 1985, 18:482-489.
56. Kuo Y.M., Duncan J.L., Westaway S.K., Yang H., Nune G., Xu E.Y., et al. Deficiency of pantothenate kinase 2 (Pank2) in mice leads to retinal degeneration and azoospermia. Hum Mol Genet 2005, 14:49-57.
57. Poli M., Derosas M., Luscieti S., Cavadini P., Campanella A., Verardi R., et al. Pantothenate kinase-2 (Pank2) silencing causes cell growth reduction, cell-specific ferroportin upregulation and iron deregulation. Neurobiol Dis 2010, 39:204-210.
58. Rana A., Seinen E., Siudeja K., Muntendam R., Srinivasan B., van der Want J.J., et al. Pantethine rescues a Drosophila model for pantothenate kinase-associated neurodegeneration. Proc Natl Acad Sci U S A 2010, 107:6988-6993.
59. Auriac A., Willemetz A., Canonne-Hergaux F. Lipid raft-dependent endocytosis: a new route for hepcidin-mediated regulation of ferroportin in macrophages. Haematologica 2010, 95:1269-1277.
60. Morgan N.V., Westaway S.K., Morton J.E., Gregory A., Gissen P., Sonek S., et al. PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron. Nat Genet 2006, 38:752-754.
61. Miyajima H. Aceruloplasminemia 1993-2003 Aug 12, University of Washington, Seattle, [updated 2008 May 15]. R.A. Pagon, T.C. Bird, C.R. Dolan, K. Stephens (Eds.).
62. De Domenico I., Ward D.M., di Patti M.C., Jeong S.Y., David S., Musci G., et al. Ferroxidase activity is required for the stability of cell surface ferroportin in cells expressing GPI-ceruloplasmin. EMBO J 2007, 26:2823-2831.
63. Curtis A.R.J., Fey C., Morris C.M., Bindoff L.A., Ince P.G., Chinnery P.F., et al. Mutation in the gene encoding ferritin light polypeptide causes dominant adult- onset basal ganglia disease. Nat Genet 2001, 28:350-354.
64. Crompton D.E., Chinnery P.F., Bates D., Walls T.J., Jackson M.J., Curtis A.J., et al. Spectrum of movement disorders in neuroferritinopathy. Mov Disord 2005, 20:95-99.
65. Levi S., Cozzi A., Arosio P. Neuroferritinopathy: a neurodegenerative disorder associated with L-ferritin mutation. Best Pract Res Clin Heamatol 2005, 18:265-276.
66. Youdim M.B.H., Ben-Shachar D., Riederer P. Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration?. Acta Neurol Scand 1989, 126:47-54.
67. Earle K.M. Studies on Parkinson's disease including x-ray fluorescent spectroscopy of formalin fixed brain tissue. J Neuropathol Exp Neurol 1968, 27:1-13.
68. Griffiths P.D., Crossman A.R. Distribution of iron in the basal ganglia and neocortex in postmortem tissue in Parkinson's disease and Alzheimer's disease. Dementia 1993, 4:61-65.
69. Uitti R.J., Rajput A.H., Rozdilsky B., Bickis M., Wollin T., Yuen W.K. Regional metal concentrations in Parkinson's disease, other chronic neurological disease, and control brains. Can J Neurol Sci 1989, 16:310-314.
70. Loeffler D.A., Connor J.R., Juneau P.I., Snyder B.S., Kanaley L., DeMaggio A.J., et al. Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions. J Neurochem 1995, 65:710-716.
71. Wypijewska A., Galazka-Friedman J., Bauminger E.R., Wszolek Z.K., Schweitzer K.J., Dickson D.W., et al. Iron and reactive oxygen species activity in parkinsonian substantia nigra. Parkinsonism Relat Disord 2010, 16:329-333.
72. Zecca L., Zucca F.A., Albertini A., Rizzio E., Fariello R.G. A proposed dual role of neuromelanin in the pathogenesis of Parkinson's disease. Neurology 2006, 67(Suppl 2):S8-S11.
73. Zecca L., Stroppolo A., Gatti A., Tampellini D., Toscani M., Gallorini M., et al. The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. PNAS 2004, 101:9843-9848.
74. Galazka-Friedman J., Bauminger E.R., Koziorowski D., Friedman A. Mössbauer spectroscopy and ELISA studies reveal differences between Parkinson's disease and control substantia nigra. Biochim Biophys Acta 2004, 1688:130-136.
75. Faucheux B.A., Martin M.E., Beaumont C., Hunot S., Hauw J.J., Hirsch E.C. Lack of upregulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson's disease. J Neurochem 2002, 83:320-330.
76. Connor J.R., Snyder B.S., Arosio P., Loeffler D.A., LeWitt P. A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer's diseased brains. J Neurochem 1995, 65:717-724.
77. Connor J.R., Boeshore K.L., Benkovic S.A., Menzies S.L. Isoforms of ferritin have a specific cellular distribution in the brain. J Neurosci Res 1994, 37:461-465.
78. Fukae J., Takanashi M., Kubo S., Nishioka K., Nakabeppu K., Mori H., et al. Expression of 8-oxoguanine DNA glycosylase (OGG1) in Parkinson's disease and related neurodegenerative disorders. Acta Neuropathol 2005, 109:256-262.
79. Dalfo E., Portero-Otin M., Ayala V., Martinez A., Pamplona R., Ferrer I. Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J Neuropathol Exp Neurol 2005, 64:816-830.
80. Dexter D.T., Carayon A., Javoy-Agid F., Agid Y., Wells F.R., Daniel S.E., et al. Alterations in the level of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991, 114:1953-1975.
81. Quintana C., Cowley J.M., Marhic C. Electron nanodiffraction and high-resolution electron microscopy studies of the structure and composition of physiological and pathological ferritin. J Struct Biol 2004, 147:166-178.
82. Galazka-Friedman J., Bauminger E.R., Szlachta K., Schweitzer K., Wszolek Z., Dickson D., et al. Mössbauer studies of pathological brain tissues affected by PSP disease. Acta Physiol Pol 2009, 115:431-433.
83. Smith M.A., Harris P.L.R., Sayre L.M., Perry G. Iron accumulation in Alzheimer disease is a source of redox generated free radicals. Proc Natl Acad Sci U S A 1997, 94:9866-9868.
84. Hallgren B., Sourander P. The effect of age on non-haemin iron in human brain. J Neurochem 1958, 3:41-51.
85. Zecca L., Swartz H.M. Total and paramagnetic metals in human substantia nigra and its neuromelanin. J Neural Transm Park Dis Dement Sect 1993, 5:203-213.